Compass Therapeutics Inc. (CMPX): Price and Financial Metrics
CMPX Price/Volume Stats
| Current price | $1.48 | 52-week high | $3.62 |
| Prev. close | $1.52 | 52-week low | $1.15 |
| Day low | $1.44 | Volume | 147,900 |
| Day high | $1.59 | Avg. volume | 473,625 |
| 50-day MA | $1.82 | Dividend yield | N/A |
| 200-day MA | $1.92 | Market Cap | 203.63M |
CMPX Stock Price Chart Interactive Chart >
Compass Therapeutics Inc. (CMPX) Company Bio
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Boston, MA.
Latest CMPX News From Around the Web
Below are the latest news stories about COMPASS THERAPEUTICS INC that investors may wish to consider to help them evaluate CMPX as an investment opportunity.
Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate DevelopmentsStrategic Clinical Advancements and Leadership Transition Announced Amidst Financial Review |
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOpened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in the second half of 2024Continue to enroll and follow patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected before the end of the |
Compass Therapeutics to Participate in Upcoming Investor EventsBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2023. Details are as follows: Stifel Healthcare Conference Location: New York, NYDate: Tuesday, November 14, 2023 Time: 9:45am ESTWebcast Link: https://wsw.c |
3 Healthcare Stocks To Make You The Millionaire Next Door: October EditionThese are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation. |
Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateContinuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023Opened 20 clinical sites and continues to enroll patients in a U.S. Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024Completed enrollment of the dose-escalation portion of the Pha |
CMPX Price Returns
| 1-mo | -25.25% |
| 3-mo | 6.47% |
| 6-mo | -12.43% |
| 1-year | -45.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -5.13% |
| 2023 | -68.99% |
| 2022 | 58.68% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...